- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Roche Pharma India forays into Ophthalmology space with launch of Vabysmo
As the world's first bispecific antibody, Vabysmo is a single molecule designed to target and inhibit the effects of two targets, providing the benefits of two medicines in one.
Bengaluru: Roche Pharma India has forayed into the Ophthalmology space by launching Vabysmo (faricimab) for the treatment of eye diseases.Neovascular or wet age-related macular degeneration (nAMD) and diabetic macular edema (DME), are two leading causes of vision loss worldwide.Vabysmo is the first and only dual-pathway-inhibitor that uniquely targets and inhibits two disease pathways linked to...
Bengaluru: Roche Pharma India has forayed into the Ophthalmology space by launching Vabysmo (faricimab) for the treatment of eye diseases.
Read also: Roche Pharma unveils multiple sclerosis treatment drug Ocrevus in India
Original news source: https://www.uniindia.com/roche-pharma-launches-vabysmo-to-treat-eye-diseases/business-economy/news/3155717.html
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751